Truvestments Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Truvestments Capital’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,684	Closed	-$94.3K	–	1226
2026 Q1	$94.3K	Hold	4,684	–	–	0.02%	390
2025 Q4	$75.6K	Buy	4,684 +3,360	+254%	+$44.5K	0.01%	385
2025 Q3	$16.1K	Hold	1,324	–	–	﹤0.01%	635
2025 Q2	$15K	Buy	+1,324	New	+$16.2K	﹤0.01%	588

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Truvestments Capital's KALV Position: Q2 2026 in Review

Truvestments Capital sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 4,684 shares — an estimated $94.3K sold.

Truvestments Capital first reported a position in KALV in Q2 2025 and held it in 4 quarters. The position peaked at $94.3K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Truvestments Capital reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Truvestments Capital sold 4,684 KalVista Pharmaceuticals shares in Q2 2026, an estimated $94.3K.
Truvestments Capital first reported a position in KalVista Pharmaceuticals in Q2 2025 and held it in 4 quarters.
Truvestments Capital's KalVista Pharmaceuticals position peaked at $94.3K in Q1 2026.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.